Primary pulmonary mucoepidermoid carcinoma (PMEC) is extremely rare. Herein, we report a case of a 71-year-old male patient with high-grade PMEC involving the right upper lobe that was successfully resected via lobectomy. As a result of invasion into the pleural and paratracheal lymph nodes, four cycles of adjuvant chemotherapy with paclitaxel and carboplatin were administered. There were no signs of relapse during 10 months of follow-up. Furthermore, we reviewed the literature and summarized the surgical approaches, prognostic factors, and underlying genetic mechanisms of PMEC, which will benefit clinical treatment.
Introduction
Smetana et al. first described pulmonary mucoepidermoid carcinoma (PMEC) in 1952. [1] [2] [3] [4] It is an extremely rare malignant neoplasm of the lung that accounts for approximately 0.1-0.2% of all lung malignancies. [3] [4] [5] [6] [7] PMEC is a salivary gland-type tumor of the lung, 5, 8 deriving from the minor salivary glands of the tracheobronchial tree 9 and has been reported to occur over an age range of 3-78 years. 3, 10, 11 Compared to other salivary gland-type tumors of the lung, there is no gender predilection in PMEC. 5, 12 According to the 2015 World Health Organization classification of lung cancer, PMEC is a mucoepidermoid carcinoma. 13 Histologically, PMEC consists of mucous-forming, epidermoid, and intermediate cells that are divided into high-grade and low-grade variants. 2, 5, 8, [13] [14] [15] As opposed to high-grade PMEC, the prognosis of low-grade PMEC is excellent, with very good five-year survival rates. 16 
Case Report
A 71-year old man with a long smoking history presented for evaluation of an asymptomatic lung mass in the right upper lobe (Table 1 , patient 1). On physical examination, his vital signs were normal and there were no abnormalities on auscultation of the chest. Enhanced chest computed tomography (CT) showed a solitary mass with heterogeneous enhancement in the apicoposterior segment of the upper lobe of the right lung (Fig 1a) . Laboratory evaluation showed elevated carcinoembryonic antigen levels (5.86 μg/L; normal range 0-5 μg/L) but no other abnormalities. The patient underwent video-assisted thoracic surgery with right upper lobectomy and lymph node dissection. Grossly, the mass measured 4 × 3.5 × 2.5 cm and was grey-white in color. On microscopic examination, all three typical cell types of mucoepidermoid carcinoma were observed (Fig 2) . Immunohistochemistry revealed that the tumor cells were diffusely positive for CK 7; partially positive for CK 5/6, p63, and TTF-1; and negative for p40, NapsinA, SOX-2, and SPA. Ki-67 was approximately 70%. The final diagnosis was high-grade PMEC with pleural and paratracheal lymph node invasion (T2aN1M0, stage II b). All resection margins were negative. Postoperative CT showed good recovery (Fig 1b) . The patient had four cycles of postoperative adjuvant chemotherapy with paclitaxel and carboplatin, and there were no signs of relapse during 10 months of follow-up. Written informed consent was obtained from all patients for the publication of this case report and accompanying images.
Discussion
Several published reviews confirm that complete surgical resection remains the best treatment choice for PMEC and can result in better long-term survival compared to nonsurgical treatment. [4] [5] [6] 12 Advanced disease at the time of initial diagnosis may make complete resection difficult, especially in cases of high-grade PMEC. Because PMEC is a type of non-small cell lung cancer, adjuvant therapy should be administered when complete resection is not possible, although the utility of chemotherapy and radiotherapy in these cases remains controversial. [5] [6] [7] 14, 17, 18 We searched medical records from Tianjin Medical University General Hospital from January 2010 to April 2017 and identified a total of eight surgically resected cases of PMEC. Table 1 displays the characteristics of the eight patients and the surgical results. Patient 6, who had advanced high-grade disease (T4N1M0; stage IIIa) underwent extensive resection but refused chemotherapy, and experienced recurrence at 14 months. Patient 4, who had poor cardiovascular status, underwent a wedge resection with a final diagnosis of low-grade PMEC with positive margins. Thus, he received two cycles of pemetrexed and nedaplatin and one cycle of gemcitabine and nedaplatin and showed no sign of relapse during 14 months of follow-up.
In addition to our in-house review, we reviewed 695 cases of PMEC from nine previous studies. Most PMECs are low/intermediate grade, and tumor locations indicate no particular tendency (Fig 3) . Complete resection of PMEC, whether high-grade or low-grade, in the absence of lymph node metastasis, yielded good prognosis, and prognostic factors predicting aggressive behavior included age, histological grade, tumor-node-metastasis stage, lymph node metastasis, and complete resection ( Table 2) .
The MECT1/3 fusion gene is common in PMEC. [8] [9] [10] In 62 patients analyzed in our systemic review, MAML2 rearrangement was much more common in low-grade (73.9%) compared to high-grade (18.8%) PMEC cases (Table 3) . Five-year overall survival was also better in the MAML2 rearrangement-positive group (94.7% vs. 64.6% in patients without MAML2 rearrangement). Thus, MAML2 rearrangement may signal a better prognosis in cases of PMEC.
Finally, in a study by Han et al., gefitinib administration was attempted to treat a case of PMEC after metastasis to the chest wall and contralateral lung. 8, 19 CT follow-up indicated that the metastatic lesions had responded to the treatment, although there was no EGFR tyrosine kinase mutation detected in the chest wall tumor. These findings suggest that PMECs with the MECT1-MAML2 fusion gene may be a valid target for tyrosine kinase inhibitor therapy. However, this hypothesis requires further investigation in a clinical setting.
In summary, complete surgical resection remains the mainstay of treatment for PMEC and can result in longterm survival. Adjuvant chemotherapy may be useful in patients with high-grade PMEC, especially in cases of lymph node involvement or intrathoracic invasion. The current literature indicates that the MECT1-MAML2 fusion gene is common in PMEC and is specific to this tumor. Identifying MAML2 rearrangement might be helpful to differentiate PMEC from other epithelial lung malignancies. MAML2 rearrangement seems to be associated with a favorable clinical outcome and PMEC cases with the MECT1-MAML2 fusion gene may exhibit a good response to tyrosine kinase inhibitor therapy.
